Artificial Intelligence in the Intensive Care Unit

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Michalina Kołodziejczak	--	2075	2023-06-02 16:44:33	\|
2	format	Jason Zhu	+ 1 word(s)	2076	2023-06-05 03:30:13	\|

This entry is adapted from the peer-reviewed paper 10.3390/jpm13060891

The development of artificial intelligence (AI) allows for the construction of technologies capable of implementing functions that represent the human mind, senses, and problem-solving skills, leading to automation, rapid data analysis, and acceleration of tasks. These solutions has been initially implemented in medical fields relying on image analysis; however, technological development and interdisciplinary collaboration allows for the introduction of AI-based enhancements to further medical specialties. During the COVID-19 pandemic, novel technologies established on big data analysis experienced a rapid expansion. Yet, despite the possibilities of advancements with these AI technologies, there are number of shortcomings that need to be resolved to assert the highest and the safest level of performance, especially in the setting of the intensive care unit (ICU). Within the ICU, numerous factors and data affect clinical decision making and work management that could be managed by AI-based technologies. Early detection of a patient’s deterioration, identification of unknown prognostic parameters, or even improvement of work organization are a few of many areas where patients and medical personnel can benefit from solutions developed with AI.

artificial intelligence intensive care unit COVID-19

1. Introduction—Pre-COVID-19 Era

Artificial intelligence (AI) is considered to be the fundamental technology of the fourth industrial revolution, with global medical agencies signaling its value in constantly evolving medical care ^[1]. By analyzing huge databases and verifying developed algorithms, it becomes possible not only to diagnose diseases earlier and more accurately but also to implement more personalized care. The Food and Drug Administration (FDA) has approved numerous devices based on artificial intelligence technology, with the list currently including 343 entries ^[2]. The first product ever approved, a ventilatory effort recorder dating back to 1995 (FDA approval year 1997), was limited in design to monitor a patient’s respiratory rate in addition to generating an audible or visual alarm when an average value did not fall within the operator-defined range ^[3]. Nowadays, these solutions are essential elements of the ventilator alerting. Over 20 years later, the FDA permitted the marketing of clinical decision-support software analyzing and notifying neurovascular specialists of a potential stroke by computed tomography (CT) imaging ^[4]. The images still require reassessment by the specialist at a clinical workstation; however, the in-advance notification of the operator could reduce the time to intervention as compared to the usual standard of care.

2. The Application of AI in the COVID-19 Pandemic

The spread of the SARS-CoV-2 virus overcame barriers of countries and continents by utilizing the possibilities of globalization, forcing international organizations to search for new crisis-management solutions. Little was known about the new disease, and it was necessary to rapidly reduce viral transmission, identify risk factors, optimize management, and reduce the burden on hospitals that faced an influx of respiratory-compromised patients. The initial unknowns were quickly followed by emerging information chaos owing to a plethora of unverified data and their lack of systematization. It was mandatory to fill this niche promptly. International organizations turned for aid to novel technologies. The European Council intensively monitored AI-based technologies that were deployed globally ^[5]. Most of them were tools for tracing contacts that aimed to contain the infection rate, especially at the early stages of the pandemic. Likewise, AI was implemented in a number of fields, mainly focused on identifying and reducing the spread of the infection (facilitating diagnosis, identifying people with fever, and detection of epidemic outbreaks), supporting research (accelerating gene sequencing, drug design, and prediction of efficacy), and optimization of hospital management (patients and staff allocation) ^[6]^[7]^[8]^[9]. The objective of achieving collective immunity to mitigate the threat of COVID-19 infections has led to the creation of various AI models focused on enhancing the vaccination process. These models increase the efficacy of vaccine distribution and identify concerns of patients regarding getting vaccinated. In the early phase of vaccination, lack of general knowledge regarding the efficacy and safety of the vaccine spanned a number of concerns that were publicly shared through online social media. Utilizing big data management and AI models, those trends can be identified and addressed by officials who can create targeted messages that address them when provided with accurate information ^[10].

The intensive work of multidisciplinary groups allowed for the development of the first AI-based technologies that could be implemented in hospitals facing the surge of COVID-19 patients. Support of the decision-making process has paramount importance when managing a large volume of patients, especially the interpretation of numerous radiological examinations to rule out non-COVID-19 causes of respiratory failure and to attempt to allocate patients who may develop a severe course of the disease. From the level of the hospital emergency department, AI-based tools for rapid COVID-19 diagnostics were created, among others, by Mount Sinai Health System (based on chest computed tomography (CT) scans and patient data) and the University of Minnesota, along with Epic Systems and M Health Fairview (chest X-rays) ^[11]^[12]. Another type of AI systems, namely software predictors, allow for the identification of hospitalized patients at high risk of clinical events, for example, intubation (COViage) and respiratory failure or low blood pressure (CLEWICU System) ^[13]^[14].

The World Health Organization (WHO) signaled that AI could be an important technology for overcoming the current global health crisis and a tool aiding sustainable recovery of populations, with an endorsed series of publications in the British Medical Journal aiming at familiarizing medical professionals with the AI technologies ^[15]. However, some authors pointed out that AI-based algorithms do not have as optimistic results as were hoped for and expected. A systematic review analyzed more than 100 proposed COVID-19 models for diagnosis and forecasting, which proved to be at high risk of statistical error, poorly reported, and overly optimistic ^[16]. Following this, the authors recommended that none of the models should be used in medical practice until those problems could be resolved. Similarly, another systematic review focusing on AI-based technologies developed for ICU use (11 predictive AI-based diagnostic models, 2 different lung segmentation software (based on deep learning) for prognosis, and 1 optimization of work in the ICU) found the studies to be at a high risk of error due to poor reporting of missing data, poor model validation, a small number of analyzed patients, or lack of inclusion of censored participants ^[17]. It is mandatory to assert that the demand for rapid-response technology interventions does not hamper the responsible design and use of AI ^[18]. Utilization of AI-specific reporting guidelines (SPIRIT-AI and CONSORT-AI) could additionally facilitate the development and quality of AI-based applications ^[19]. Formally, the FDA seeks to oversee and modify the dynamic process of ensuring the safety of patients who can benefit from the implementation of new technologies in their treatment. Technology is advancing rapidly, which also requires changes to systems for reviewing and providing opinions on rapidly evolving medical devices ^[20].

3. Artificial Intelligence in the COVID-19 Intensive Care Unit (ICU)

Patients requiring ICU hospitalization have compromised chances of survival on their own and have to be supported with invasive treatment techniques related to decompensation of the cardiovascular and respiratory systems’ function. Hospitalization in the ICU also requires a significant individualization of patients’ treatment plans and focuses on a scholastic analysis of their whole clinical profile. Comprehensive intensive management significantly increases the time and resources that must be dedicated to patients’ care. Due to the course of the disease and the rapid emergence of large numbers of COVID-19 patients who required respiratory therapy, prone positioning, renal replacement therapy (RRT), or extracorporeal membrane oxygenation (ECMO), ICUs and their staff became swiftly overwhelmed. New ICU stations were created in rapidly adapted departments to provide the possibility of intensive care for as many patients as possible. After the initial resources crisis, when not enough personal protective equipment (PPE), ventilators, and ICU stations were available—a problem that could not be quickly resolved—there was a shortage of competent intensive healthcare professionals able to operate equipment and manage critical patients. In a short time, efforts were made to train non-intensive care personnel, an initiative that usually takes years under normal training conditions. A possible solution arose: to utilize clinically applicable AI-based technologies to support the decisions of healthcare professionals. The development of such technologies requires close interdisciplinary collaboration between AI developers and medical experts, especially because of the amount and implications of the information used by ICU healthcare professionals. Moreover, the role of AI in such a dynamic setting must be innovative in order to not disrupt the process of patient care and clinical decision making.

Researchers started with development of tools that would help to predict the outcomes of the COVID-19 patients and adequately modify management to increase survival and allocate critical resources in the most optimal manner. A number of machine learning models were built to identify predictors of outcomes in the COVID-19 ICU ^[21]. Based on retrospective (596 patients) and prospective (443 patients) clinical data, AI technology distinguished predictors associated with ICU survival (age, inflammatory and thrombotic activity, and severity of ARDS on admission to the ICU), ECMO therapy (age, pulmonary dysfunction, and transfer from an outside facility), and RRT (interaction of patient age with D-dimer levels on admission and creatinine levels with SOFA score without Glasgow Coma Score). Similarly, a COVID-19 critical care consortium, i.e., ECMOCARD, was established to characterize the evolution of clinical parameters based on data from 633 mechanically ventilated COVID-19 patients in 20 ICUs in Great Britain during the first wave of the pandemic (1 March–31 August 2020) ^[21]. Using techniques of machine learning and explainable artificial intelligence, complete clinical data within 48 h of ICU admission to death or discharge were analyzed. In critically ill COVID-19 patients, pronation increased the oxygen level in only 45% of patients; those with blood clots or inflammation in the lungs, lower oxygen levels, lower blood pressure, and higher blood lactic acid levels were less likely to benefit from a prone position. Additionally, the effectiveness of the prone position decreased the later it was applied; thus, the authors suggested that patients who are unresponsive may be referred to other interventions such as ECMO. The authors created an online tool based on the initial database that could be utilized by everyone free of charge ^[22]. It must be emphasized, however, that the data were collected during the first wave of COVID-19 pandemic, and they might not be replicable with the course of disease altered by new mutations and management. This prompts continuous data accumulation and the development of comprehensive and preferably international COVID-19-specific databases. Artificial intelligence was also used in early detection and diagnosis, in which AI algorithms may examine chest X-rays, CT scans, and other medical imaging to identify signs of COVID-19 infection. For example, Kuo et al. assessed the performance of an AI model in detecting COVID-19 on chest X-rays in patients with respiratory symptoms from a cohort of 5894 patients across three different continents ^[23]. The AI model achieved a sensitivity of 79.1% and a specificity of 60.5%. When compared to radiologists from Asia, the U.S., and Europe, by using an independent dataset of 852 positive and negative COVID-19 cases, the AI program achieved a sensitivity of 82.9% and a specificity of 56.8% compared to the radiologists’ sensitivity of 51.6% and specificity of 99.1%. The authors concluded that the study size and scope provided valuable insights into realistic performance expectations for AI systems predicting COVID-19 on chest X-rays and the challenges of creating truly “generalizable” diagnostic AI models even when using an objective standard such as PCR testing. This phenomenon is applicable in numerous AI models and systems, highlighting the need for validation of those novel technologies in clinical practice.

Another application of AI in COVID-19 intensive care is to predict the risk of more severe illness on initial presentation. Lazzarini et al. presented a machine learning model that could predict severe cases of COVID-19 such as acute respiratory distress syndrome (ARDS) and emphasized various risk factors that significantly impact disease progression ^[24]. The study was based on a cohort of 289,351 COVID-19 patients. Researchers demonstrated that the machine learning model “Gradient Boosting Decision Tree” achieved the highest performance, with a 40% increase in efficiency compared to another older models. Furthermore, a comparison of the model’s predictive abilities with the predictions of five clinicians indicated that the model is on par with or outperforms the experts in terms of precision and recall. The most contributing diagnoses can be easily retrieved from a patient’s clinical history and can be used for early screening of infected patients. The authors concluded that the proposed model could be a promising tool to deploy in a healthcare setting to facilitate and optimize the care of COVID-19 patients. In another study, the predictive models employed learned from historical data to predict the development of ARDS, a severe outcome in COVID-19 cases ^[25].

References

Harjola, V.-P.; Mebazaa, A.; Celutkiene, J.; Bettex, D.; Bueno, H.; Chioncel, O.; Crespo-Leiro, M.G.; Falk, V.; Filippatos, G.; Gibbs, S.; et al. Contemporary management of acute right ventricular failure: A statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur. J. Heart Fail. 2016, 18, 226–241.
Wu, M.Y.; Chang, Y.S.; Huang, C.C.; Wu, T.I.; Lin, P.J. The impacts of baseline ventilator parameters on hospital mortality in acute respiratory distress syndrome treated with venovenous extracorporeal membrane oxygenation: A retrospective cohort study. BMC Pulm. Med. 2017, 17, 181.
Bunge, J.J.H.; Caliskan, K.; Gommers, D.; Reis Miranda, D. Right ventricular dysfunction during acute respiratory distress syndrome and veno-venous extracorporeal membrane oxygenation. J. Thorac. Dis. 2018, 10 (Suppl. S5), S674–S682.
Pappalardo, F.; Pieri, M.; De Bonis, M.; Maj, G.; Calabrò, M.G.; Ajello, S.; Melisurgo, G.; Zangrillo, A. Cardiac support with IABP during venovenous ECMO for ARDS. Intensive Care Med. 2013, 39, 1152–1153.
Chotalia, M.; Ali, M.; Alderman, J.E.; Kalla, M.; Parekh, D.; Bangash, M.N.; Patel, J.M. Right Ventricular Dysfunction and Its Association with Mortality in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome. Crit. Care Med. 2021, 49, 1757–1768.
Cho, A. AI systems aim to sniff out coronavirus outbreaks. Science 2020, 368, 810–811.
Zhang, K.; Liu, X.; Shen, J.; Li, Z.; Sang, Y.; Wu, X.; Zha, Y.; Liang, W.; Wang, C.; Wang, K.; et al. Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography. Cell 2020, 181, 1423–1433.e11.
Randhawa, G.S.; Soltysiak, M.P.M.; El Roz, H.; de Souza, C.P.E.; Hill, K.A.; Kari, L. Machine learning using intrinsic genomic signatures for rapid classification of novel pathogens: COVID-19 case study. PLoS ONE 2020, 15, e0232391.
Bragazzi, N.L.; Dai, H.; Damiani, G.; Behzadifar, M.; Martini, M.; Wu, J. How Big Data and Artificial Intelligence Can Help Better Manage the COVID-19 Pandemic. Int. J. Environ. Res. Public Health 2020, 17, 3176.
Guerdoux, G.; Tiffet, T.; Bousquet, C. Inference Time of a CamemBERT Deep Learning Model for Sentiment Analysis of COVID Vaccines on Twitter. Stud. Health Technol. Inform. 2022, 295, 269–270.
Sato, R.; Dugar, S.; Cheungpasitporn, W.; Schleicher, M.; Collier, P.; Vallabhajosyula, S.; Duggal, A. The impact of right ventricular injury on the mortality in patients with acute respiratory distress syndrome: A systematic review and meta-analysis. Crit. Care 2021, 25, 172.
Lazzeri, C.; Bonizzoli, M.; Batacchi, S.; Cianchi, G.; Franci, N.; Socci, F.; Peris, A. Persistent Right Ventricle Dilatation in SARS-CoV-2-Related Acute Respiratory Distress Syndrome on Extracorporeal Membrane Oxygenation Support. J. Cardiothorac. Vasc. Anesth. 2022, 36, 1956–1961.
Vieillard-Baron, A.; Schmitt, J.-M.; Augarde, R.; Fellahi, J.L.; Prin, S.; Page, B.; Beauchet, A.; Jardin, F. Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: Incidence, clinical implications, and prognosis. Crit. Care Med. 2001, 29, 1551–1555.
Grignola, J.C.; Domingo, E. Acute Right Ventricular Dysfunction in Intensive Care Unit. BioMed Res. Int. 2017, 2017, 8217105.
Li, Y.; Li, H.; Zhu, S.; Xie, Y.; Wang, B.; He, L.; Zhang, D.; Zhang, Y.; Yuan, H.; Wu, C.; et al. Prognostic Value of Right Ventricular Longitudinal Strain in Patients with COVID-19. JACC Cardiovasc. Imaging 2020, 13, 2287–2299.
Wynants, L.; Van Calster, B.; Collins, G.S.; Riley, R.D.; Heinze, G.; Schuit, E.; Bonten, M.M.J.; Dahly, D.L.; Damen, J.A.; Debray, T.P.A.; et al. Prediction models for diagnosis and prognosis of COVID-19: Systematic review and critical appraisal. BMJ 2020, 369, m1328.
Chee, M.L.; Ong, M.E.H.; Siddiqui, F.J.; Zhang, Z.; Lim, S.L.; Ho, A.F.W.; Liu, N. Artificial Intelligence Applications for COVID-19 in Intensive Care and Emergency Settings: A Systematic Review. Int. J. Environ. Res. Public Health 2021, 18, 4749.
Röösli, E.; Rice, B.; Hernandez-Boussard, T. Bias at warp speed: How AI may contribute to the disparities gap in the time of COVID-19. J. Am. Med. Inform. Assoc. JAMIA 2021, 28, 190–192.
McLean, B. Hemodynamics of Acute Right Heart Failure in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome. Crit. Care Nurs. Clin. N. Am. 2015, 27, 449–467.
Squara, P.; Dhainaut, J.F.; Artigas, A.; Carlet, J. Hemodynamic profile in severe ARDS: Results of the European Collaborative ARDS Study. Intensive Care Med. 1998, 24, 1018–1028.
Magunia, H.; Lederer, S.; Verbuecheln, R.; Gilot, B.J.; Koeppen, M.; Haeberle, H.A.; Mirakaj, V.; Hofmann, P.; Marx, G.; Bickenbach, J.; et al. Machine learning identifies ICU outcome predictors in a multicenter COVID-19 cohort. Crit. Care 2021, 25, 295.
Cherpanath, T.G.; Landburg, P.P.; Lagrand, W.K.; Schultz, M.J.; Juffermans, N.P. Effect of extracorporeal CO2 removal on right ventricular and hemodynamic parameters in a patient with acute respiratory distress syndrome. Perfusion 2016, 31, 525–529.
Kuo, M.D.; Chiu, K.W.H.; Wang, D.S.; Larici, A.R.; Poplavskiy, D.; Valentini, A.; Napoli, A.; Borghesi, A.; Ligabue, G.; Fang, X.H.B.; et al. Multi-center validation of an artificial intelligence system for detection of COVID-19 on chest radiographs in symptomatic patients. Eur. Radiol. 2023, 33, 23–33.
Lazzarini, N.; Filippoupolitis, A.; Manzione, P.; Eleftherohorinou, H. A machine learning model on Real World Data for predicting progression to Acute Respiratory Distress Syndrome (ARDS) among COVID-19 patients. PLoS ONE 2022, 17, e0271227.
Jiang, X.; Coffee, M.; Bari, A.; Wang, J.; Jiang, X.; Huang, J.; Shi, J.; Dai, J.; Cai, J.; Zhang, T.; et al. Towards an Artificial Intelligence Framework for Data-Driven Prediction of Coronavirus Clinical Severity. Comput. Mater. Contin. 2020, 63, 537–551.

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Critical Care Medicine

Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Michalina Marta Kołodziejczak

Katarzyna Sierakowska

Yurii Tkachenko

Piotr Kowalski

View Times: 224

Update Date: 05 Jun 2023

Table of Contents

Video Upload Options

Confirm

1. Introduction—Pre-COVID-19 Era

2. The Application of AI in the COVID-19 Pandemic

3. Artificial Intelligence in the COVID-19 Intensive Care Unit (ICU)

References